The molecular profile of metastatic melanoma in Australia
- 1 February 2016
- journal article
- Published by Elsevier BV in Pathology
- Vol. 48 (2), 188-193
- https://doi.org/10.1016/j.pathol.2015.12.008
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibThe New England Journal of Medicine, 2015
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated MelanomaThe New England Journal of Medicine, 2014
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in MelanomaThe New England Journal of Medicine, 2014
- A Landscape of Driver Mutations in MelanomaCell, 2012
- Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic MelanomaClinical Cancer Research, 2012
- Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic TrialsPLOS ONE, 2012
- NRAS mutation status is an independent prognostic factor in metastatic melanomaCancer, 2011
- Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanomaPigment Cell & Melanoma Research, 2011
- Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic MelanomaJournal of Clinical Oncology, 2011
- Mutations of the BRAF gene in human cancerNature, 2002